Vineet Laboratories Limited
Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and fine chemicals primarily in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl… Read more
Vineet Laboratories Limited (VINEETLAB) - Net Assets
Latest net assets as of September 2025: ₹142.21 Million INR
Based on the latest financial reports, Vineet Laboratories Limited (VINEETLAB) has net assets worth ₹142.21 Million INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹906.45 Million) and total liabilities (₹764.24 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹142.21 Million |
| % of Total Assets | 15.69% |
| Annual Growth Rate | 148.73% |
| 5-Year Change | -44.96% |
| 10-Year Change | N/A |
| Growth Volatility | 2379.81 |
Vineet Laboratories Limited - Net Assets Trend (2017–2025)
This chart illustrates how Vineet Laboratories Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Vineet Laboratories Limited (2017–2025)
The table below shows the annual net assets of Vineet Laboratories Limited from 2017 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹146.48 Million | -57.82% |
| 2024-03-31 | ₹347.24 Million | +3.09% |
| 2023-03-31 | ₹336.83 Million | +1.40% |
| 2022-03-31 | ₹332.18 Million | +24.81% |
| 2021-03-31 | ₹266.15 Million | +6572.13% |
| 2020-03-31 | ₹3.99 Million | -2.71% |
| 2019-03-31 | ₹4.10 Million | +4000.00% |
| 2018-03-31 | ₹100.00K | 0.00% |
| 2017-03-31 | ₹100.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vineet Laboratories Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5923700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₹92.19 Million | 62.94% |
| Other Comprehensive Income | ₹113.52 Million | 77.50% |
| Total Equity | ₹146.48 Million | 100.00% |
Vineet Laboratories Limited Competitors by Market Cap
The table below lists competitors of Vineet Laboratories Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Inomin Mines Inc
V:MINE
|
$2.24 Million |
|
Transwarranty Finance Limited
NSE:TFL
|
$2.24 Million |
|
Recrusul S/A
SA:RCSL3
|
$2.24 Million |
|
Bank of Southside Virginia Corporation The
PINK:BSSC
|
$2.24 Million |
|
Kardan Israel Ltd
TA:KRDI
|
$2.24 Million |
|
Prospech Ltd
AU:PRS
|
$2.24 Million |
|
Meihua International Medical Technologies Co Ltd
NASDAQ:MHUA
|
$2.24 Million |
|
GENMAB (GE9.SG)
STU:GE9
|
$2.24 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vineet Laboratories Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 347,243,000 to 146,476,000, a change of -200,767,000 (-57.8%).
- Net loss of 201,910,000 reduced equity.
- Other comprehensive income decreased equity by 141,530,000.
- Other factors increased equity by 142,673,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹-201.91 Million | -137.85% |
| Other Comprehensive Income | ₹-141.53 Million | -96.62% |
| Other Changes | ₹142.67 Million | +97.4% |
| Total Change | ₹- | -57.82% |
Book Value vs Market Value Analysis
This analysis compares Vineet Laboratories Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.83x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2674.43x to 1.83x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-03-31 | ₹0.01 | ₹29.01 | x |
| 2018-03-31 | ₹0.01 | ₹29.01 | x |
| 2019-03-31 | ₹0.44 | ₹29.01 | x |
| 2020-03-31 | ₹0.43 | ₹29.01 | x |
| 2021-03-31 | ₹28.87 | ₹29.01 | x |
| 2022-03-31 | ₹36.03 | ₹29.01 | x |
| 2023-03-31 | ₹36.54 | ₹29.01 | x |
| 2024-03-31 | ₹37.53 | ₹29.01 | x |
| 2025-03-31 | ₹15.89 | ₹29.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vineet Laboratories Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -137.85%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -26.92%
- • Asset Turnover: 0.79x
- • Equity Multiplier: 6.45x
- Recent ROE (-137.85%) is below the historical average (-17.88%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -2.78% | 0.00% | 609.77x | 1.00x | ₹-509.92K |
| 2021 | 6.69% | 0.73% | 2.24x | 4.09x | ₹-8.81 Million |
| 2022 | 19.98% | 3.47% | 1.43x | 4.02x | ₹33.17 Million |
| 2023 | 3.72% | 0.59% | 1.83x | 3.44x | ₹-21.16 Million |
| 2024 | 2.96% | 0.68% | 1.29x | 3.37x | ₹-24.45 Million |
| 2025 | -137.85% | -26.92% | 0.79x | 6.45x | ₹-216.56 Million |
Industry Comparison
This section compares Vineet Laboratories Limited's net assets metrics with peer companies in the Chemicals industry.
Industry Context
- Industry: Chemicals
- Average net assets among peers: $7,566,417,574
- Average return on equity (ROE) among peers: 17.58%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vineet Laboratories Limited (VINEETLAB) | ₹142.21 Million | -2.78% | 5.37x | $2.24 Million |
| Archean Chemical Industries Limited (ACI) | $18.64 Billion | 8.70% | 0.28x | $374.06 Million |
| Amines & Plasticizers Limited (AMNPLST) | $189.73 Million | 16.38% | 2.50x | $10.36 Million |
| The Andhra Sugars Limited (ANDHRSUGAR) | $8.95 Billion | -0.54% | 0.68x | $60.92 Million |
| Bhansali Engineering Polymers Limited (BEPL) | $10.02 Billion | 17.96% | 0.10x | $88.83 Million |
| Chemplast Sanmar Limited (CHEMPLASTS) | $4.98 Billion | 35.86% | 4.35x | $183.76 Million |
| DCW Limited (DCW) | $6.32 Billion | -0.68% | 1.88x | $69.23 Million |
| Deepak Fertilizers and Petrochemicals Corporation Limited (DEEPAKFERT) | $8.10 Billion | 16.91% | 1.17x | $685.82 Million |
| Deepak Nitrite Limited (DEEPAKNTR) | $15.72 Billion | 38.87% | 1.04x | $1.09 Billion |
| DIAMINES AND CHEMICALS ORD (BSE) (DIAMINESQ) | $651.80 Million | 36.80% | 0.17x | $9.53 Million |
| DMCC SPECIALITY CHEMICALS LIMITED (DMCC) | $2.10 Billion | 5.53% | 0.80x | $22.00 Million |